<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132194</url>
  </required_header>
  <id_info>
    <org_study_id>DPSG-1517</org_study_id>
    <nct_id>NCT03132194</nct_id>
  </id_info>
  <brief_title>Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Single-center, Double-blind, Randomized, Parallel-group Study, Comparing DPSG to a Placebo Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the therapeutic effect of DPSG and Placebo gel in the treatment of acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group study comparing
      DPSG to ACZONE Gel and active treatment to a Placebo control in the treatment of Acne
      Vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2016</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in non-inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of success</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1125</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>DPSG 7.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPSG 7.5% (Taro Pharmaceuticals USA)
Topical, twice daily on the face for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo product (Taro Pharmaceuticals Inc.)
Topical, twice daily on the face for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aczone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dapsone 7.5
Topical, twice daily on the face for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPSG 7.5%</intervention_name>
    <description>topical gel</description>
    <arm_group_label>DPSG 7.5%</arm_group_label>
    <other_name>dapsone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aczone</intervention_name>
    <description>topical gel</description>
    <arm_group_label>Aczone</arm_group_label>
    <other_name>dapsone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical gel</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non pregnant female aged â‰¥ 12 years with a clinical diagnosis of acne
             vulgaris.

        Exclusion Criteria:

          -  Female Subjects who are pregnant, nursing or planning to become pregnant during study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catawba Research</last_name>
    <role>Study Chair</role>
    <affiliation>http://catawbaresearch.com/contact/</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

